share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham重申对blueprint medicines的买入评级,维持$135的目标股价
Benzinga ·  2024/11/15 18:07  · 评级/大行评级

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $135 price target.

Needham分析师Ami Fadia重申了blueprint medicines(纳斯达克:BPMC)的买入评级,并维持135美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发